Literature DB >> 1174327

[Studies of the metabolism and excretion of silybin in the rat].

H Bülles, J Bülles, G Krumbiegel, W H Mennicke, D Nitz.   

Abstract

The metabolism and excretion of silybin (as N-methyl-glucamine salt) was investigated after intravenous and oral administration to rats. In the urine, silybin was excreted mostly in the unchanged form after intravenous as well as oral application, whilst in the bile it appeared above all in the form of metabolites. By hydrolysis with arylsulfatase/beta-glucuronidase, the metabolites were identified as sulfate and glucuronide conjugates of silybin and dehyrosilybin; the latter appeared in small quantities as a dehydrated product of silybin. After intravenous injection of 20 mg silybin per kg body weight, the excreted amount of silybin after 48 h was 8%, whereas 76% was eliminated in the bile within the same period of time. After oral application of 2--20 mg silybin/kg body weight 20% after 40 mg/kg 35% and after 120 mg/kg 20% of the administered silybin was excreted in the bile during 48 h. The maximum excretion rate was achieved at application of 20 mg/kg p.o. after 1 h. At this dosage, 2--5% was eliminated within the same time in the urine. The excretion of silybin mainly took place (more than 80% of the total of excreted bilybin) in the bile, both after oral and intravenous administration.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1174327

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

1.  Comparative pharmacokinetics of silipide and silymarin in rats.

Authors:  P Morazzoni; A Montalbetti; S Malandrino; G Pifferi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

2.  On the nephrotoxicity of alpha-amanitin and the antagonistic effects of silymarin in rats.

Authors:  G Vogel; R Braatz; U Mengs
Journal:  Agents Actions       Date:  1979-06

3.  Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.

Authors:  C Bokemeyer; L M Fels; T Dunn; W Voigt; J Gaedeke; H J Schmoll; H Stolte; H Lentzen
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.